During a Targeted Oncology™ Case-Based Roundtable™ event, Renuka Iyer, MD, discussed subgroup analyses of the HIMALAYA trial of frontline durvalumab plus tremelimumab for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Renuka Iyer, MD, discussed the study designs, patient populations, and efficacy outcomes of the IMbrave150 and HIMALAYA trials of frontline immunotherapy-containing regimens for patients with hepatocellular carcinoma. This is the first of 2 articles based on this event.
Milind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.
Richard Kim, MD, walks through options in the frontline setting for patients with advanced staged hepatocellular carcinoma and how newer treatments have impacted this patient population.